Revolution Medicines and Summit Therapeutics have entered into a clinical collaboration to evaluate the safety and efficacy of three RAS(ON) inhibitors in combination with ivonescimab, a PD-1/VEGF bispecific antibody, across multiple solid tumor settings. The partnership aims to explore novel combination therapies for patients with RAS-addicted cancers, representing a significant advancement in targeted oncology treatment approaches.
Collaboration Details and Drug Portfolio
The clinical collaboration will evaluate Revolution Medicines' three clinical-stage RAS(ON) inhibitors: daraxonrasib (RMC-6236), a multi-selective inhibitor; zoldonrasib (RMC-9805), a G12D-selective inhibitor; and elironrasib (RMC-6291), a G12C-selective inhibitor. These compounds will be tested in combination with Summit Therapeutics' ivonescimab, a PD-1/VEGF bispecific antibody.
"We've disclosed promising initial evidence that each of daraxonrasib and elironrasib can deliver additive antitumor activity safely when combined with a PD-1 antibody in first-line treatment of patients with RAS mutant non-small cell lung cancer," said Mark A. Goldsmith, M.D., Ph.D., chairman and chief executive officer of Revolution Medicines. "Combinations with novel PD-1 bispecific inhibitors could unlock further therapeutic potential."
Target Tumor Types and Study Structure
The clinical collaboration will focus on three priority tumor types: RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC). Under the agreement terms, Summit Therapeutics will supply ivonescimab for clinical research while Revolution Medicines will serve as the study sponsor.
Each company will retain commercial rights to their respective compounds, and the agreement is structured as mutually non-exclusive, allowing both parties flexibility in future partnerships and development strategies.
Strategic Rationale and Clinical Potential
"We're thrilled to partner with Revolution Medicines to evaluate in a clinical setting how our highly promising ivonescimab combined with their compelling RAS(ON) inhibitors could potentially improve outcomes for patients with lung and gastrointestinal cancers," said Robert W. Duggan, Chairman and Co-Chief Executive Officer and Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics.
The collaboration builds on Revolution Medicines' existing clinical evidence demonstrating the potential for additive antitumor activity when RAS(ON) inhibitors are combined with PD-1 antibodies. The partnership seeks to leverage ivonescimab's differentiated profile as a PD-1/VEGF bispecific inhibitor to potentially enhance therapeutic outcomes across common RAS mutant cancers.
Company Backgrounds and Development Pipelines
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. Beyond the three compounds in the current collaboration, Revolution Medicines anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development.
Summit Therapeutics is a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company continues to rapidly advance the development of ivonescimab across non-small cell lung cancer and other solid tumors, seeking to combine the drug with promising medicines and drug candidates to provide innovative therapy options for patients facing high unmet needs.
